Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera versus high-dose Octreotide LAR in progressive somatostatin receptor-positive midgut neuroendocrine tumors
2011-005049-11Phase 3Unknown
- Sponsor
- Advanced Accelerator Applications
- Start
- Dec 2011
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in midgut carcinoid tumor comparing Lutathera plus best supportive care with High-dose Sandostatin LAR comparator (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
lutetium Lu 177 dotatateoctreotide
03
Conditions
midgut carcinoid tumor
Beyond the preview
Go deeper on 2011-005049-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005049-11.